Vertigenius raises EUR 2.55 million for US expansion
Vertigenius has raised €2.55 million to expand in the US, where its device is already in use in clinics.
The funding round was led by Atlantic Bridge, with backing from Enterprise Ireland, MedTech Syndicate, IRRUS Investments, Xcendra Ventures, Ascentifi and other investors. It follows an earlier €2.1 million raise in 2024.
The Irish medical technology company makes a wearable head sensor for people undergoing vertigo rehabilitation. The device allows clinicians to monitor patients as they carry out treatment at home and to adjust prescribed exercises based on remotely collected data.
Vertigenius completed FDA registration before launching in the US in October 2025. Its device is now used in 20 clinics across 11 states, and around 3,000 patients have been treated so far.
Vertigo affects balance and can be triggered by concussion, traumatic brain injury and age-related decline in the balance system. Many patients recover through vestibular therapy and home-based exercises, but clinicians have historically had limited visibility between appointments.
US Push
The new funding will be used to drive commercial growth in the US, which Vertigenius values at more than €3 billion. The country has more than 5,000 vestibular clinics, making it the company's primary focus for expansion.
Part of the investment will go towards expanding its US commercial team, with two US sales directors recently joining the business.
Vertigenius also plans to hire in clinical research, product research and development, quality assurance and regulatory affairs. Those roles will remain based at the company's headquarters in Ireland.
The business also highlighted a reimbursement route for remote therapeutic monitoring in the US. It says clinics can generate about USD $220 in net new income per patient through the mechanism, where no equivalent revenue had previously been available in vestibular rehabilitation.
Mark Barry, chief executive of Vertigenius, said: "For the first time, clinicians have a direct view of at-home patient treatment. By transforming real-time data into clinically relevant insights, providers can now proactively tailor treatments and significantly elevate the standard of patient care they provide.
"This investment marks an exciting new chapter for Vertigenius as we move into the world's largest market for vestibular care. The early traction we have seen in the US validates both the clinical value of our platform and the commercial opportunity."
Atlantic Bridge said it saw an opportunity in an area of healthcare where patients often need support between in-person visits. It described the vertigo treatment market as large and with an unmet monitoring need.
Conor O'Sullivan, investment director at Atlantic Bridge, said: "Vertigenius is addressing a significant gap in vestibular care in a multi-billion dollar market. The team has built a unique platform that is significantly enhancing the delivery of vestibular care by supporting clinicians and patients between visits, and we are excited to back their U.S. expansion."
According to the company, 390 million people worldwide are affected by vertigo, which it describes as common and often debilitating despite being treatable. The latest fundraise gives Vertigenius fresh capital as it tries to turn its early US clinic footprint into broader commercial adoption.